FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed group of inventions relates to medicine, namely to endocrinology, and deals with treating diabetes mellitus of type 2. For this purpose a therapeutically effective quantity of means inhibiting the activation or signalisation of NKG2D, or blocking the interaction of NKG2D ligand binding is introduced.
EFFECT: method provides the effective treatment of type 2 diabetes, including the correction of such manifestations of it as the cardiovascular system pathology, inflammatory and metabolic components.
27 cl, 14 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| REGULATION OF METABOLISM USING MIR-378 | 2011 |
|
RU2585491C2 |
| LIGAND GITR AND MOLECULES AND ANTIBODIES BOUND WITH LIGAND GITR, AND VERSIONS OF THEIR APPLICATION | 2004 |
|
RU2369636C2 |
| COMPOSITIONS OF HUMANISED NOTCH FUSED PROTEINS AND METHODS OF TREATING | 2008 |
|
RU2532830C2 |
| MODIFIED MONOCYTES/MACROPHAGES EXPRESSING CHIMERIC ANTIGEN RECEPTORS AND THEIR APPLICATIONS | 2016 |
|
RU2766690C2 |
| PEPTIDES OF DIRECTED ACTION OF VEGFR-1/NRP-1 | 2008 |
|
RU2488592C2 |
| HYBRID PROTEINS BASED ON HUMAN Notch3 AS TRAPS-INHIBITORS OF Notch3 SIGNAL TRANSMISSION | 2009 |
|
RU2567662C2 |
| TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
| MICA BINDING AGENTS | 2013 |
|
RU2656183C2 |
| T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS | 2013 |
|
RU2653761C2 |
| THERAPEUTIC USE OF THE TLR AGONIST AND COMBINED THERAPY | 2011 |
|
RU2603467C2 |
